Bank of America’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,446
| Closed | -$2.31K | – | 5870 |
|
|
2025
Q4 | $2.31K | Sell |
1,446
-5,435
| -79% | -$11.2K | ﹤0.01% | 6391 |
|
|
2025
Q3 | $17.6K | Buy |
6,881
+5,334
| +345% | +$16.8K | ﹤0.01% | 7096 |
|
|
2025
Q2 | $2.8K | Buy |
1,547
+28
| +2% | +$46 | ﹤0.01% | 7383 |
|
|
2025
Q1 | $3.08K | Sell |
1,519
-1,791
| -54% | -$6.69K | ﹤0.01% | 7280 |
|
|
2024
Q4 | $19.8K | Sell |
3,310
-1,921
| -37% | -$16K | ﹤0.01% | 6846 |
|
|
2024
Q3 | $51.1K | Buy |
5,231
+642
| +14% | +$8.63K | ﹤0.01% | 6537 |
|
|
2024
Q2 | $94K | Buy |
4,589
+1,628
| +55% | +$54.5K | ﹤0.01% | 6272 |
|
|
2024
Q1 | $134K | Sell |
2,961
-3,560
| -55% | -$170K | ﹤0.01% | 6103 |
|
|
2023
Q4 | $308K | Buy |
6,521
+123
| +2% | +$6.84K | ﹤0.01% | 5819 |
|
|
2023
Q3 | $259K | Sell |
6,398
-10,539
| -62% | -$1.07M | ﹤0.01% | 5742 |
|
|
2023
Q2 | $1.8M | Sell |
16,937
-4,371
| -21% | -$1.46M | ﹤0.01% | 4309 |
|
|
2023
Q1 | $6.36M | Buy |
21,308
+14,035
| +193% | +$5.99M | ﹤0.01% | 3292 |
|
|
2022
Q4 | $2.5M | Sell |
7,273
-443
| -6% | -$107K | ﹤0.01% | 4056 |
|
|
2022
Q3 | $1.46M | Sell |
7,716
-957
| -11% | -$222K | ﹤0.01% | 4576 |
|
|
2022
Q2 | $1.83M | Sell |
8,673
-3,537
| -29% | -$744K | ﹤0.01% | 4386 |
|
|
2022
Q1 | $4.08M | Buy |
12,210
+3,398
| +39% | +$985K | ﹤0.01% | 3842 |
|
|
2021
Q4 | $2.87M | Buy |
8,812
+4,830
| +121% | +$2.07M | ﹤0.01% | 4202 |
|
|
2021
Q3 | $1.93M | Sell |
3,982
-949
| -19% | -$417K | ﹤0.01% | 4485 |
|
|
2021
Q2 | $2.29M | Sell |
4,931
-212
| -4% | -$116K | ﹤0.01% | 4213 |
|
|
2021
Q1 | $3.55M | Buy |
5,143
+943
| +22% | +$759K | ﹤0.01% | 3735 |
|
|
2020
Q4 | $3.1M | Buy |
4,200
+257
| +7% | +$200K | ﹤0.01% | 3566 |
|
|
2020
Q3 | $2.73M | Buy |
3,943
+1,034
| +36% | +$776K | ﹤0.01% | 3435 |
|
|
2020
Q2 | $2.47M | Buy |
2,909
+2,729
| +1,516% | +$1.78M | ﹤0.01% | 3447 |
|
|
2020
Q1 | $65K | Buy |
180
+18
| +11% | +$6.47K | ﹤0.01% | 5755 |
|
|
2019
Q4 | $38K | Sell |
162
-171
| -51% | -$17.2K | ﹤0.01% | 6330 |
|
|
2019
Q3 | $38K | Buy |
333
+258
| +344% | +$40.7K | ﹤0.01% | 6407 |
|
|
2019
Q2 | $14K | Sell |
75
-56
| -43% | -$9.49K | ﹤0.01% | 6647 |
|
|
2019
Q1 | $21K | Buy |
+131
| New | +$16.2K | ﹤0.01% | 6487 |
|
|
2018
Q4 | – | Sell |
-12
| Closed | -$1K | – | 7118 |
|
|
2018
Q3 | $1K | Buy |
+12
| New | +$1.78K | ﹤0.01% | 7106 |
|
|
2018
Q2 | – | Sell |
-53
| Closed | -$9K | – | 7090 |
|
|
2018
Q1 | $9K | Buy |
+53
| New | +$8.85K | ﹤0.01% | 6627 |
|
Other funds holding BTAI
AC
OCM
VCM
VFT
Bank of America's BTAI Position: Q1 2026 in Review
Bank of America sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 1,446 shares — an estimated $2.31K sold.
Bank of America first reported a position in BTAI in Q1 2018 and held it in 30 quarters. The position peaked at $6.36M in Q1 2023. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.
- Bank of America reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 1,446 BioXcel Therapeutics shares in Q1 2026, an estimated $2.31K.
- Bank of America first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 30 quarters.
- Bank of America's BioXcel Therapeutics position peaked at $6.36M in Q1 2023.
- 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.